Synopsis:
Fundamentally sound businesses with strong financials and strong earnings, such as GPT Infraprojects, Natco Pharma, Shakti Pumps, and Symphony Ltd., are trading 30–50% below their 52-week highs, offering possible value opportunities.
Strong financials, such as high ROE, low debt, consistent profit growth, and strong business models, are preferred by many investors. However, due to overvaluation, short-term issues, or market sentiment, even these strong companies may experience a significant decline in their stock prices. This brings up a crucial query: Is this an opportunity to purchase at a reduced price or an indication of more serious issues?
In order to determine whether these companies are good investments or stocks to stay away from, let’s examine a few of them, looking at their valuations, news, and recent performance.
GPT Infraprojects Ltd
With its headquarters located in Kolkata, India, GPT Infraprojects Limited is the flagship company of the GPT Group and has more than 40 years of experience in infrastructure development and civil construction. The production of railway concrete sleepers and infrastructure projects are the company’s two main areas of activity.
It specializes in carrying out EPC (Engineering, Procurement, and Construction) contracts in a number of industries, such as industrial infrastructure, power, roads, and railroads. Road and highway development, metro infrastructure, railway track and steel bridge construction, bridge fabrication, erection, and maintenance are all included in its service portfolio.
GPT Infraprojects is one of the few Indian businesses that manufactures concrete sleepers with a substantial global presence in addition to its strong domestic presence. It has operations in Ghana, Namibia, and South Africa. Serving key government clients, the company plays a vital role in national development and is recognized for its commitment to building essential infrastructure.
With a market valuation of Rs. 1,561 crores, GPT Infraprojects, currently trading at Rs. 124, which is at a discount of 41 percent from its 52-week high of Rs. 204. It has a price-to-earnings ratio of 21.1x, which is marginally lower than the industry average of 24.3x and suggests a fair valuation. The business’s return on equity (ROE) of 17.92 percent and return on capital employed (ROCE) of 21.8 percent showed effective use of capital.
Regarding profitability, the company reported a net profit of Rs. 22.23 crore for Q4FY25, with profit growth of 46.67 percent YoY compared to 15 crores in Q4FY24 and sales growth of 29.15 percent from Rs. 295 crores in Q4FY24 to Rs. 381 crores in Q4FY25. Its debt-to-equity ratio is low at 0.25, indicating manageable leverage.
Natco Pharma Ltd
The pharmaceutical company NATCO Pharma Limited was founded in 1981 and is headquartered in Hyderabad. It is a well-known pharmaceutical company with a vertically integrated business model and a strong emphasis on research and development. It creates, produces, and sells intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations (FDFs). Serving both domestic and international markets, NATCO has nine advanced manufacturing and research facilities spread throughout India.
Natco Pharma distributes its goods in more than 50 nations, with the US, India, Canada, and Brazil being its main markets. Additionally, it is found in places like Australia and Southeast Asia.
Natco Pharma, with a market capitalization of Rs. 17,495 crores, is trading at Rs. 1,010, which is at a discount of 38.2 percent from its 52-week high of Rs. 1,639. It is showing signs of possible undervaluation with a low P/E ratio of 9.35x, which is significantly lower than the industry average of 33.5x. The business’s impressive ROE of 28 percent and ROCE of 32.8 percent demonstrate strong capital returns.
With modest growth in profits of 5.2 percent YoY from Rs. 386 crores in Q4FY24 to Rs. 406 crores in Q4FY25, and sales grew by 14.33 percent YoY to Rs. 1,221 crores in Q4FY25 as compared to Rs. 1,068 crores in Q4FY24. The firm maintains a debt-free balance sheet with a debt-to-equity ratio of just 0.04.
Shakti Pumps (India) Ltd
Shakti Pumps, founded i n 1982 and headquartered in Pithampur, Madhya Pradesh, is a leading manufacturer of energy-efficient pumps and motors with a strong focus on sustainability and innovation.
With a product portfolio of over 1,200 indigenously developed solutions, the company serves sectors like agriculture, irrigation, water supply, wastewater management, and industrial applications. It operates a large-scale manufacturing facility with an annual capacity of 5 lakh pumps and exports to over 120 countries. With more than four decades of industry experience, the company stands out as one of the few with complete in-house capabilities for manufacturing both pumps and motors.
As a major player in solar-powered pumping, Shakti holds a dominant 25 percent market share in the PM-KUSUM scheme, contributing significantly to India’s renewable energy efforts. The company invests 3–4 percent of its net profit in R&D and holds over 15 patents.
Shakti Pumps, with a market valuation of Rs. 11,246 crores, is trading at Rs. 938, which is at a discount of 33.1 percent from its 52-week high of Rs. 1,398. It has an attractively lower P/E ratio of 27.6x than the industry average of 45.9x. With a ROE of 42.61 percent and a ROCE of 55.31 percent, the business is effectively demonstrating strong returns on invested capital.
Regarding profitability, the company reported a net profit of Rs. 110 crores for Q4FY25, with profit growth of 22.22 percent YoY compared to Q4FY24 of Rs. 90 crores and sales growth of 9.2 percent from Rs. 609 crores in Q4FY24 to Rs. 665 crores in Q4FY25. Its debt-to-equity ratio is low at 0.14, indicating manageable leverage.
Symphony Ltd
The largest air cooler manufacturer in the world by volume, Symphony Limited, was established in Gujarat in 1988 and has operations in more than 60 countries. The business turned an unorganized industry into a global leader in its field by being a pioneer in evaporative air-cooling.
Symphony is the industry leader in the residential, commercial, and industrial cooling segments and is renowned for its design innovation, energy efficiency, and customer focus. The company actively contributes to mitigating climate change while providing cost-effective and sustainable cooling solutions, thanks to its robust R&D and engineering capabilities. A publicly traded business, Symphony is dedicated to providing value to all of its stakeholders.
With a market capitalization of Rs. 8030 crores, Symphony was trading at Rs. 1,170, which is at a discount of 38 percent from its 52-week high of Rs. 1,879. It has a P/E ratio of 32.4x, which is lower than the industry P/E of 54.9x, pointing to possible undervaluation. The company shows healthy financials with an ROE of 32.4 percent and ROCE of 36.8 percent, underscoring effective capital use.
In Q4FY25, Symphony reported Rs. 79 crores in net profit, with profit growth of 64.58 percent YoY from Rs. 49 crores in Q4FY24 and sales growth of 46.99 percent from Rs. 332 crores in Q4FY24 to Rs. 488 crores in Q4FY25, demonstrating a very strong performance. It has a low debt-to-equity ratio of 0.19.
Written by Akshay Sanghavi
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
